A phase I clinical trial (KEYNOTE-001) indicated that patients with advanced non-small cell lung cancer who had received radiotherapy before treating with Pembrolizumab, a PD-1 inhibitor, achieved longer progression-free survival and overall survival compared with those without radiotherapy [40]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.